Use este identificador para citar ou linkar para este item: http://higia.imip.org.br/handle/123456789/703
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorBairi, Khalid El-
dc.contributor.authorHaynes, Harry R.-
dc.contributor.authorBlackley, Elizabeth-
dc.contributor.authorFineberg, Susan-
dc.contributor.authorShear, Jeffrey-
dc.contributor.authorTurner, Sophia-
dc.contributor.authorFreitas, Juliana Ribeiro de-
dc.contributor.authorSur, Daniel-
dc.contributor.authorAmendola, Luis Claudio-
dc.contributor.authorGharib, Masoumeh-
dc.contributor.authorKallala, Amine-
dc.contributor.authorArun, Indu-
dc.contributor.authorAzmoudeh-Ardalan, Farid-
dc.contributor.authorFujimoto, Luciana-
dc.contributor.authorSua, Luz F.-
dc.contributor.authorLiu, Shi-Wei-
dc.contributor.authorLien, Huang-Chun-
dc.contributor.authorKirtani, Pawan-
dc.contributor.authorBalancin, Marcelo-
dc.contributor.authorAttar, Hicham El-
dc.contributor.authorGuleria, Prerna-
dc.contributor.authorYang, Wenxian-
dc.contributor.authorShash, Emad-
dc.contributor.authorChen, I-Chun-
dc.contributor.authorBautista, Veronica-
dc.contributor.authorMoura, Jose Fernando do Prado-
dc.contributor.authorRapoport, Bernardo L.-
dc.contributor.authorCastaneda, Carlos-
dc.contributor.authorSpengler, Eunice-
dc.contributor.authorAcosta-Haab, Gabriela-
dc.contributor.authorFrahm, Isabel-
dc.contributor.authorSanchez, Joselyn-
dc.contributor.authorCastillo, Miluska-
dc.contributor.authorBouchmaa, Najat-
dc.contributor.authorZin, Reena R. Md-
dc.contributor.authorShui, Ruohong-
dc.contributor.authorOnyuma, Timothy-
dc.contributor.authorYang, Wentao-
dc.contributor.authorHusain, Zaheed-
dc.contributor.authorWillard-Gallo, Karen-
dc.contributor.authorCoosemans, An-
dc.contributor.authorPerez, Edith A.-
dc.contributor.authorProvenzano, Elena-
dc.contributor.authorEricsson, Paula Gonzalez-
dc.contributor.authorRichardet, Eduardo-
dc.contributor.authorMehrotra, Ravi-
dc.contributor.authorSarancone, Sandra-
dc.contributor.authorEhinger, Anna-
dc.contributor.authorRimm, David L.-
dc.contributor.authorBartlett, John M. S.-
dc.contributor.authorViale, Giuseppe-
dc.contributor.authorDenkert, Carsten-
dc.contributor.authorHida, Akira I.-
dc.contributor.authorSotiriou, Christos-
dc.contributor.authorLoibl, Sibylle-
dc.contributor.authorHewitt, Stephen M.-
dc.contributor.authorBadve, Sunil-
dc.contributor.authorSymmans, William Fraser-
dc.contributor.authorKim, Rim S.-
dc.contributor.authorPruneri, Giancarlo-
dc.contributor.authorGoel, Shom-
dc.contributor.authorFrancis, Prudence A.-
dc.contributor.authorInurrigarro, Gloria-
dc.contributor.authorYamaguchi, Rin-
dc.contributor.authorGarcia-Rivello, Hernan-
dc.contributor.authorHorlings, Hugo-
dc.contributor.authorAfqir, Said-
dc.contributor.authorSalgado, Roberto-
dc.contributor.authorAdams, Sylvia-
dc.contributor.authorKok, Marleen-
dc.contributor.authorDieci, Maria Vittoria-
dc.contributor.authorMichiels, Stefan-
dc.contributor.authorDemaria, Sandra-
dc.contributor.authorLoi, Sherene-
dc.contributor.authorInternational Immuno-Oncology Biomarker Working Group-
dc.date.accessioned2022-06-08T12:45:41Z-
dc.date.available2022-06-08T12:45:41Z-
dc.date.issued2021-
dc.identifier.urihttp://higia.imip.org.br/handle/123456789/703-
dc.description.abstractThe advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.pt_BR
dc.language.isoenpt_BR
dc.subjectNeoplasmspt_BR
dc.subjectImmunotherapypt_BR
dc.subjectLymphocytespt_BR
dc.titleThe tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Grouppt_BR
dc.higia.programArtigos científicos colaboradores IMIPpt_BR
dc.higia.tipoArtigo Científicopt_BR
dc.higia.pages17 p.pt_BR
Aparece nas coleções:Artigos

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Moura JFP et al.-2021.pdf234.86 kBAdobe PDFVisualizar/Abrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.